Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders

1 - 26 . (canceled)

27 . A method of treating an autoimmune or inflammatory disease or disorder comprising the inhibition of Glepp-1 with a composition comprising a Glepp-1 inhibitor of Formula (I):

its geometrical isomers, optically active forms or its racemic forms, wherein:

A is selected from the group consisting of C 1 -C 12 -alkyl, C 1 -C 8 alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated C 3 -C 9 -cycloalkyl, heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl;

R 1 is selected from the group consisting of H, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy and halogen;

B is any one of B1 through B22;

D is either selected from the group consisting of D1, D2 and D3:

with m being an integer selected from 0, 1 or 2 and n being an integer selected from 1 or 2; and R 3 is H or C 1 -C 6 alkyl; or D4

with n being an integer selected from 0 or 1;

R is selected from the group consisting of C 1 -C 12 -alkyl, C 1 -C 8 alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated C 3 -C 8 -cycloalkyl, heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl and C 2 -C 6 -alkynyl heterocycloalkyl.

28 . The method according to claim 27 , wherein the disease or disorder is selected from the group consisting of inflammatory bowel diseases, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, diversion colitis irritable bowel syndrome, neuroinflammation, multiple sclerosis, Guillan Barre syndrome, chronic inflammatory polyneuropathy (CIPN), lung diseases, respiratory distress syndrome, joint and bone diseases, osteoarthritis, rheumatoid arthritis, liver diseases, liver fibrosis, cirrhosis, chronic liver disease, fibrotic diseases, lupus, glomerulosclerosis, systemic sclerosis skin fibrosis, post-radiation fibrosis, cystic fibrosis, vascular pathologies, atherosclerosis, cardiomyopathy, myocardial infarction, restenosis, degenerative diseases of the central nervous system, amyotrophic lateral sclerosis, inflammatory disorders of the skin, scleroderma and psoriasis.

29 . The method according to claim 27 , wherein the Glepp-1 inhibitor is a carboxylic acid of Formula (Ia):

30 . The method according to claim 27 , wherein A is C 4 -C 6 -alkyl aryl or n-butylphenyl.

31 . The method according to claim 27 , wherein B is B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B12, B16, B17, B20 or B22.

32 . The method according to claim 27 , wherein R is a C 4 -C 6 -alkyl.

33 . The method according to claim 27 , wherein A is a phenyl group substituted by a C 1 -C 4 -alkyl or a halogen; B is either B1, B2, B3 or B12; R is C 4 -C 6 -alkyl, C 3 -C 8 -cycloalkyl or C 1 -C 6 -alkyl cycloalkyl; and D is selected from:

34 . The method according to claim 27 , wherein the Glepp-1 inhibitor is a carbolic acid of Formula (Ib) or Formula (Ic):

wherein A is a C 1 -C 6 -alkyl aryl or thiazolyl; and B is B1, B3, B4, B5, B11, B14 or B18.

35 . The method according to claim 33 , wherein the Glepp-1 inhibitor is selected from the group consisting of:

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]-2-fluorobenzoic acid;

4-({{4-[(4-butylphenyl)ethynyl]benzyl}[2-(4-chlorophenyl)ethyl]amino}-methyl)benzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(3-phenylpropyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(1-naphthylmethyl)amino]-2-hydroxybenzoic acid;

5-((4-tert-butylbenzyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

4-[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]-2-hydroxybenzoic acid;

2-fluoro-5-{hexyl[4-(phenylethynyl)benzyl]amino}benzoic acid;

5-[{4-[(4-chlorophenyl)ethynyl]benzyl}(hexyl)amino]-2-hydroxybenzoic acid;

5-(hexyl {4-[(4-methoxyphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[hexyl(4-{[4-(trifluoromethyl)phenyl]ethynyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclopentylmethyl)amino]-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(3,3-dimethylbutyl)amino]-2-fluorobenzoic acid;

5-((cyclopentylmethyl){4-[(4-methoxyphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(ethyl)amino]-2-fluorobenzoic acid;

5-(hexyl {4-[(4-propylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(pentyl)amino]-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(methyl)amino]-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclopropylmethyl)amino]-2-fluorobenzoic acid;

5-{butyl[4-(phenylethynyl)benzyl]amino}-2-fluorobenzoic acid;

2-fluoro-5-[[4-(phenylethynyl)benzyl](propyl)amino]benzoic acid;

2-fluoro-5-[{4-[(4-fluorophenyl)ethynyl]benzyl}(hexyl)amino]benzoic acid;

2-fluoro-5-(hexyl {4-[(4-propylphenyl)ethynyl]benzyl}amino)benzoic acid;

5-{{4-[(4-butylphenyl)ethynyl]benzyl}[(2-carboxycyclopropyl)methyl]amino}-2-fluorobenzoic acid;

5-[{4-[(4-ethylphenyl)ethynyl]benzyl}(hexyl)amino]-2-fluorobenzoic acid;

5-[{4-[(4-tert-butylphenyl)ethynyl]benzyl}(hexyl)amino]-2-fluorobenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]phenyl}(hexyl)amino]methyl}-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(isobutyl)amino]-2-fluorobenzoic acid;

5-[(1-{4-[(4-butylphenyl)ethynyl]phenyl}pentyl)oxy]-2-hydroxybenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]benzoyl}(hexyl)amino]methyl}-2-hydroxybenzoic acid;

5-{[F {2-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-hydroxybenzoic acid;

4-((3-cyclopentylpropyl){{[(4-fluorophenyl)ethynyl]benzoyl}amino}-2-hydroxybenzoic acid;

4-[{4-[(4-butylphenyl)ethynyl]benzoyl}(3-cyclopentylpropyl)amino]-2-hydroxybenzoic acid;

5-{[{4-[(4-fluorophenyl)ethynyl]benzoyl}(hexyl)amino]methyl}-2-hydroxybenzoic acid;

5-{[{4-[(4-chlorophenyl)ethynyl]benzoyl}(hexyl)amino]methyl}-2-hydroxybenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexyl)amino]carbonyl}-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzoyl}(hexyl)amino]-2-fluorobenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]benzoyl}(hexyl)amino]methyl}-2-fluorobenzoic acid; and

4-[{4-[(4-chlorophenyl)ethynyl]benzoyl}(3-cyclopentylpropyl)amino]-2-hydroxybenzoic acid.

36 . The method according to claim 27 , wherein the Glepp-1 inhibitor is an alkynyl aryl carboxamide according to Formula (II), which Formula (II) is selected from any of Formulae (IIa), (IIb), (IIc) or (IId):

geometrical isomers, enantiomers, diastereomers and racemic forms thereof, wherein:

A is a C 2 -C 15 -alkynyl, C 2 -C 6 -alkynyl aryl, or C 2 -C 6 -alkynyl heteroaryl;

Cy is an aryl, an heteroaryl, a C 3 -C 8 -cycloalkyl or an heterocycle group; n is 0 or 1;

R 1 and R 2 are each independently selected from hydrogen or C 1 -C 6 -alkyl; and

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, C 1 -C 6 -alkyl carboxy, aryl, heteroaryl, saturated or unsaturated C 3 -C 8 -cycloalkyl, heterocycloalkyl, acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl, and C 2 -C 6 -alkynyl heterocycloalkyl.

37 . The method according to claim 36 , wherein R 1 and R 2 are each H, Cy is a phenyl group, and A is a moiety of the formula —C≡C—R 6 wherein R 6 is phenyl, C 1 -C 12 -alkyl phenyl, C 2 -C 6 -alkenyl phenyl, or C 2 -C 6 -alkynyl phenyl.

38 . The method according to claim 37 , wherein the Glepp-1 inhibitor is selected from the group consisting of:

4-[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclopentylpropanoyl)amino]-2-hydroxy-benzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(hexanoyl)amino]2-hydroxybenzoic acid;

5-((4-tert-butylbenzoyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-((biphenyl-4-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid;

5-((1,3-benzodioxol-5-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-([(benzyloxy)acetyl]{4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(4-hexylbenzoyl)amino]-2-hydroxybenzoic acid;

5-((1-benzothien-2-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl}-2-hydroxybenzoic acid;

(4-{[{4-[(4-butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl}phenoxy)acetic acid;

8-[{4-[(4-butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid;

4-{[{4-[(4-butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]methyl}-benzoic acid;

5-[{4-[(4-chlorophenyl)ethynyl]benzyl}(2-thienylacetyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-chlorophenyl)ethynyl]benzyl}(2-thienylacetyl)amino]-2-hydroxybenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid;

5-[{4-[(4-butylphenyl)ethynyl]benzyl}(3,3-dimethylbutanoyl)amino]-2-fluorobenzoic acid;

4-[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid;

4-[{4-[(4-butylphenyl)ethynyl]benzyl}(hexanoyl)amino]-2-hydroxybenzoic acid;

4-[{4-[(4-butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid;

4-[{4-[(4-tert-butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid;

4-((3-cyclopentylpropanoyl){4-[(4-propoxyphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid;

4-((3-cyclopentylpropanoyl){4-[(4-propylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid; and

5-{[{4-[(4-butylphenyl)ethynyl]benzyl}(cyclopentylpropanoyl)amino]methyl}-2-hydroxybenzoic acid.

39 . The method according to claim 27 , wherein the Glepp-1 inhibitor is an aryl dicarboxamide according to Formula (III), which Formula (III) is selected from any of the Formulae (IIIa), (IIIb) or (IIIc):

isomers, enantiomers, diastereomers or racemates thereof, wherein:

A is an aminocarbonyl moiety of the formula —CO—NHR 6 wherein R 6 is C 6 -C 15 -alkyl, C 2 -C 15 -alkenyl, C 2 -C 15 -alkynyl, a C 3 -C 8 -cycloalkyl, C 1 -C 6 alkyl-C3-C8 cycloalkyl, phenyl, C 1 -C 12 -alkyl phenyl, C 2 -C 6 -alkenyl phenyl or C 2 -C 6 -alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

R 1 and R 2 are each independently selected from hydrogen or C 1 -C 6 -alkyl; and

R 3 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl amine, C 1 -C 6 -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated C 3 -C 8 -cycloalkyl, heterocycloalkyl, acyl moiety, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl aryl, C 2 -C 6 -alkenyl heteroaryl, C 2 -C 6 -alkynyl aryl, C 2 -C 6 -alkynyl heteroaryl, C 1 -C 6 -alkyl cycloalkyl, C 1 -C 6 -alkyl heterocycloalkyl, C 2 -C 6 -alkenyl cycloalkyl, C 2 -C 6 -alkenyl heterocycloalkyl, C 2 -C 6 -alkynyl cycloalkyl and C 2 -C 6 -alkynyl heterocycloalkyl.

40 . The method according to claim 39 , wherein R 1 and R 2 are each H, Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl and thiazolyl-phenyl and R 6 is selected from the group consisting of C 8 -C 12 -alkyl, and C 1 -C 4 -alkyl phenyl which may be substituted by C 1 -C 8 -alkyl or phenoxy.

41 . The method according to claim 40 , wherein the Glepp-1 inhibitor is selected from the group consisting of:

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}-benzyl)amino]-2-hydroxybenzoic acid;

5-((4-cyanobenzoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

(4-{[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid; and

(4-{[[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl](3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid.

42 . The method according to claim 27 , wherein the Glepp-1 inhibitor is a substituted methylene amide derivative of Formula (IV):

isomers, enantiomers, diastereomers, salts or racemates thereof, wherein:

R 1 is selected from C 1 -C 12 -alkyl, C 2 -C 12 -alkenyl, C 1 -C 12 -alkynyl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or heterocycloalkyl, C 1 -C 12 -alkyl-aryl or C 1 -C 12 -alkyl-heteroaryl, C 2 -C 12 -alkenyl-aryl or -heteroaryl, or C 2 -C 12 -alkynyl-aryl or -heteroaryl;

R 2a and R 2b are each independently selected from H or C 1 -C 12 -alkyl; and

Cy is an aryl, heteroaryl, cycloalkyl or heterocycle group.

43 . The method according to claim 42 , wherein:

R 2a and R 2b are each H;

R 1 is -CA 1 A 2 A 3 whereby each of A 1 , A 2 , A 3 is independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, phenyl and thienyl, which may be substituted by cyano, halogen, methoxy, hydroxy, phenoxy, —NO 2 or trifluoromethyl; and Cy is a thienyl, phenyl or biphenyl being substituted by —SO 2 R 3 or —CO—NR 3 R 3′ in which R 3′ is H and R 3 is C 7 -C 15 -alkyl or C 8 -C 15 -alkyl or a dodecyl group which may be substituted by a halogen, whereby however at least two of A 1 , A 2 , A 3 are not hydrogen, methyl, ethyl or propyl.

44 . The method according to claim 43 , wherein the Glepp-1 inhibitor has the Formula (V):

isomers, enantiomers, diastereomers, salts, and racemates thereof, wherein:

R 1 is selected from the group consisting of phenyl, benzyl, phenethyl, and 1-methylbenzyl which may be substituted by C 1 -C 6 -alkyl group or a cycloalkyl group;

Cy is a phenyl or a biphenyl group substituted with a moiety selected from the group consisting of —NH—CO—R 3 , —CO—NH—R 3 , and an oxadiazole group substituted with R 3 , wherein R 3 is C 7 -C 15 -alkyl, C 8 -C 15 -alkyl or a dodecyl group.

45 . The method according to claim 43 , wherein the Glepp-1 inhibitor is selected from the group consisting of:

{{4-[(4-hexylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid;

(benzyl {4-[(pentadecylamino)carbonyl]benzyl}amino)(oxo)acetic acid;

({[1-(tert-butoxycarbonyl)-4-piperidinyl]methyl}{4-[(dodecylamino)carbonyl]-benzyl}amino)(oxo)acetic acid;

oxo {{4-[(9E)-9-tetradecenoylamino]benzyl}[4-(trifluoromethyl)benzyl]amino}acetic acid;

oxo {[4-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-acetic acid;

oxo {(4-tetradec-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino}acetic acid;

{(4-dodec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

oxo {{1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid;

([(2-butyl-1-benzofuran-3-yl)methyl]{4-[(dodecylamino)carbonyl]benzyl}amino)-(oxo)acetic acid;

{(4-{[(4-octylphenyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid;

{{cyclopentyl[4-(trifluoromethyl)phenyl]methyl}[4-(tridecanoylamino)benzyl]-amino}(oxo)acetic acid;

oxo([4-(trifluoromethyl)benzyl]{[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthyl]-methyl}amino)acetic acid;

{{cyclopentyl[4-(trifluoromethyl)phenyl]methyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic acid;

([2-(3-chlorophenyl)ethyl]{4-[(1Z)-dec-1-enyl]benzyl}amino)(oxo)acetic acid;

{[2-(3-chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-(oxo)acetic acid;

oxo {{(1R)-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid;

oxo {[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}-acetic acid;

oxo {{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}acetic acid;

((4-dec-1-ynylbenzyl){1-[4-(trifluoromethyl)phenyl]ethyl}amino)(oxo)acetic acid;

{{1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino}(oxo)acetic acid;

{{[4-(dodecyloxy)-1-naphthyl]methyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

((4-dec-1-ynylbenzyl){1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}amino)-(oxo)acetic acid;

{(4-dec-1-ynylbenzyl)[4 (trifluoromethyl)benzyl]amino}(oxo)acetic acid;

oxo {[4-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]-amino}acetic acid;

{(4-dodecylbenzyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(3,5-dichlorobenzyl) [4-(tridecanoylamino)benzyl]amino}(oxo)acetic acid;

{{4-[(4-octylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

oxo {[4-(trifluoromethyl)benzyl][4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino}-acetic acid;

{{4-[2-(4-octylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(4-{[4-(heptyloxy)phenyl]ethynyl}benzyl) [4-(trifluoromethyl)benzyl]amino}(oxo)-acetic acid;

{{4-[(4-butylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[[2-(3-chlorophenyl)ethyl](4-dodec-1-ynylbenzyl)amino](oxo)acetic acid;

{(4-{[4-(benzyloxy)phenyl]ethynyl}benzyl)[4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid;

{{4-[2-(4-hexylphenyl)ethyl]benzyl}[4 (trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{{4-[2-(4-hexylphenyl)ethyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{[4-(11-hydroxyundecyl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(4-dodec-1-ynylbenzyl) [4-(trifluoromethyl)phenyl]amino}(oxo)acetic acid;

{{4-[(4-octylbenzoyl)amino]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{[(3-dec-1-ynyl-1-benzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid;

{[(3-dodec-1-ynyl-1-benzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino}-(oxo)acetic acid;

oxo {({3-[(4-propylphenyl)ethynyl]-1-benzofuran-5-yl}methyl) [4-(trifluoromethyl)-benzyl]amino}acetic acid;

[(4-dodec-1-ynylbenzyl)(4-fluorobenzyl)amino](oxo)acetic acid;

[bis(4-oct-1-ynylbenzyl)amino](oxo)acetic acid;

{[(6-dodec-1-ynylpyridin-3-yl)methyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

[(4-dodec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

([1-(3-chlorophenyl)-1-methylethyl]{4-[(4-hexylphenyl)ethynyl]benzyl}amino)-(oxo)acetic acid;

oxo {[4-(trifluoromethyl)benzyl][4-(4-undecyl-1,3-thiazol-2-yl)benzyl]amino}acetic acid;

({4-[(4-hexylphenyl)ethynyl]benzyl}{1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl}-amino)(oxo)acetic acid;

{[4-(5-cyclohexylpent-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{{3-[(4-hexylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(4-dec-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(4-dodec-1-yn-1-ylphenyl)[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

((3-chlorobenzyl){4-[(4-hexylphenyl)ethynyl]benzyl}amino)(oxo)acetic acid;

{{4-[(4-hexylphenyl)ethynyl]benzyl}[2-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

((4-chlorobenzyl){4-[(4-hexylphenyl)ethynyl]benzyl}amino)(oxo)acetic acid;

{{2-[(4-hexylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{[4-(11-fluoroundec-1-yn-1-yl)benzyl][4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

{(4-non-1-yn-1-ylbenzyl) [4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

({4-[(4-butylphenyl)ethynyl]benzyl}{1-methyl-1-[4-(trifluoromethyl)phenyl]-ethyl}amino)(oxo)acetic acid;

[{4-[(4-butylphenyl)ethynyl]benzyl}(diphenylmethyl)amino](oxo)acetic acid;

{{4-[(4-hexylphenyl)ethynyl]phenyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid;

oxo {{4-[(4-pentylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}acetic acid;

{{4-[(4-heptylphenyl)ethynyl]benzyl}[4-(trifluoromethyl)benzyl]amino}(oxo)acetic acid; and

5-[(carboxycarbonyl)(4-dec-1-yn-1-ylbenzyl)amino]-2-hydroxybenzoic acid.

46 . The method according to claim 27 , wherein the Glepp-1 inhibitor is a compound of Formula (VI):

isomers, enantiomers, diastereomers, salts or racemates thereof, wherein:

R 2 is a phenyl which is fused with an aryl or an heteroaryl, or R 2 is a thienyl or furanyl, R 3 is iodine or phenyl and n is a integer of 0-4.

47 . The method according to claim 46 , wherein n is 1.

48 . The method according to claim 27 , wherein the Glepp-1 inhibitor is a compound of Formula (VII):

isomers, enantiomers, diastereomers, salts and racemates thereof, wherein:

m′ is 0, 1 or 2 and p is an integer from 1 to 3;

A is O, or a bond, B is arylene, heteroarylene, heterocycloalkylene, cycloalkylene or phenyl;

R 8 is selected from the group comprising or consisting of H, halogen, hydroxy, acyl, amino, carboxy, cyano, nitro, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkyl carboxy, C 1 -C 6 -alkyl acyl, C 1 -C 6 -alkyl alkoxycarbonyl, C 1 -C 6 -alkyl aminocarbonyl, C 1 -C 6 -alkyl acyloxy, acylamino, C 1 -C 6 -alkyl acylamino, ureido, C 1 -C 6 -alkyl ureido, C 1 -C 6 -alkyl carbamate, C 1 -C 6 -alkyl amino, C 1 -C 6 alkoxy, C 1 -C 6 -alkyl alkoxy, sulfanyl, C 1 -C 6 -alkyl sulfanyl, sulfinyl, C 1 -C 6 -alkyl sulfinyl, sulfonyl, sulfonylamino, C 1 -C 6 -alkyl sulfonyl, C 1 -C 6 -alkyl sulfonylaminoaryl, aryl, heteroaryl, C 3 -C 8 -cycloalkyl or heterocycloalkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl-aryl or -heteroaryl, and C 2 -C 6 -alkynyl aryl or -heteroaryl.

49 . The method according to claim 27 , wherein the Glepp-1 inhibitor is administered in combination with a co-agent useful in the treatment of an autoimmune and/or an inflammatory disorder.

50 . A pharmaceutical composition comprising a Glepp-1 inhibitor or any one of Formulae I through VII, a co-agent useful in the treatment of an autoimmune and/or an inflammatory disorder and a pharmaceutically acceptable excipient.

51 . The pharmaceutical composition according to claim 50 , wherein the co-agent is interferon beta.